Novartis seeks accelerated FDA approval for pelabresib
诺华目前预计将在年底前与FDA讨论 pelabresib 可能获得加速批准一事，首席执行官瓦斯·纳拉西姆汉在周二的电话会上对投资者表示。
English original
Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.
在周二的投资者电话会上
原始出处
Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid报道摘要
For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia and neutropenia are among some serious side effects tied to the drug that ...
fiercepharma.com